

August 14, 2025

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sirs,

Sub: Outcome of the Board meeting held on Thursday, August 14, 2025

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Thursday, August 14, 2025, the Board of Directors considered and approved the unaudited financial results of the Company for the quarter ended June 30, 2025. The said unaudited financial results together with the Limited Review Report of the Statutory Auditors dated August 14, 2025 are enclosed herewith.

The press release with regard to the same is also enclosed herewith.

The meeting commenced at 11:00 A.M. and concluded at 1:40 P.M. (IST).

Please take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**



Manasa. R
Company Secretary



Encl: As above

Statement of unaudited financial results for the quarter ended 30 June 2025

SI No.	Particulars	'Rs in millions except for earnings per share data			
		Quarter ended 30/06/2025	Quarter ended 31/03/2025	Quarter ended 30/06/2024	Year ended 31/03/2025
		Unaudited	Refer Note 5	Unaudited	Audited
1	Income				
	a) Revenue from operations	5,263.1	4,804.8	3,875.2	17,162.9
	b) Other income	112.4	161.5	83.5	406.3
	Total income	5,375.5	4,966.3	3,958.7	17,569.2
2	Expenses				
	(a) Cost of materials consumed	94.9	942.5	458.5	2,871.3
	(b) Purchase of stock-in-trade	4,175.9	2,878.6	2,403.3	10,088.2
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,316.7)	(1,225.0)	(557.4)	(3,329.4)
	(d) Employee benefit expense	644.5	660.7	609.6	2,574.4
	(e) Depreciation and amortisation expense	165.7	176.9	39.1	399.9
	(f) Allowance for expected credit loss (net)	22.1	(9.4)	(10.2)	6.6
	(g) Selling, marketing and distribution expense	220.2	220.2	183.7	848.7
	(h) Other expenses	611.1	473.5	407.0	1,563.4
	(i) Finance costs	7.2	6.8	1.1	14.6
	Total expenses	4,624.9	4,124.8	3,534.7	15,037.7
3	Profit before exceptional items and tax (1-2)	750.6	841.5	424.0	2,531.5
4	Add/(Less): Exceptional items (Refer Note 4)	(3.6)	(56.8)	(575.6)	(967.9)
5	Profit / (loss) before tax (3+4)	747.0	784.7	(151.6)	1,563.6
6	Tax expense				
	(a) Current tax	221.0	229.2	103.1	601.0
	(b) Tax expense for prior years	-	-	4.4	4.4
	(c) Deferred tax charge / (credit)	(32.3)	(27.0)	(141.2)	(199.2)
	Total tax expense	188.7	202.2	(33.7)	406.2
7	Profit / (loss) after tax (5-6)	558.3	582.5	(117.9)	1,157.4
8	Other comprehensive income/ (loss)				
	Items that will not be reclassified to profit or loss				
	(a) Re-measurement gains / (losses) on post employment benefit obligations	8.2	19.6	9.9	(15.6)
	(b) Income tax effect on above	(2.1)	(5.0)	(2.5)	3.9
	Other comprehensive income/ (loss), net of income tax	6.1	14.6	7.4	(11.7)
9	Total comprehensive income / (loss) for the period (7+8)	564.4	597.1	(110.5)	1,145.7
10	Paid-up equity share capital (Face value of Rs 2/- per equity share)	50.0	50.0	50.0	50.0
11	Other Equity	-	-	-	7,653.5
12	Earnings per equity share of Rs 2/- each (basic and diluted)	22.33	23.30	(4.72)	46.30




Initialled For
Identification
Purpose Only

Statement of unaudited financial results for the quarter ended 30 June 2025

Notes:

- 1 The Statements of Financial Results have been prepared in accordance with the applicable Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the "Act") [Companies (Indian Accounting Standards) Rules, 2015 (as amended)] and other accounting principles generally accepted in India.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no segment information has been provided.
- 3 During the quarter ended 30 June 2025, the operations at the manufacturing site have ceased and decommissioning of the plant and machinery has started. Accordingly, the plant and machinery relevant to the manufacturing site are fully depreciated.
- 4 Exceptional Items:
 - a During an earlier year, the Company had made an announcement to Stock exchanges about its intention to exit the Company's manufacturing site in Bangalore in due course of time. The Company had subsequently started exploring the option to sell the manufacturing site in a fully operational manner to a Contract Manufacturing Organization (CMO). However, on June 21, 2024, the Board resolved that the Company would instead, explore to find a suitable buyer for its manufacturing site and exit in due course. Exceptional items for the quarter ended year 30 June 2025, 31 March 2025, 30 June 2024 and year ended 31 March 2025 consists of expenses related to closure of the manufacturing site.
 - b The exceptional items for the year ended 31 March 2025 also consists of employee separation cost amounting to Rs. 331.5 Million for restructuring of Biopharmaceuticals Business Unit in line with strategy of the Company to become a specialist focussed organisation, bring innovative medicines faster and transform patient outcome.
- 5 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year 31 March 2025 and the published unaudited year-to-date figures up to the third quarter of the respective financial year i.e., 31 December 2024 which were subjected to limited review by the statutory auditors.
- 6 This Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 14 August 2025. The statutory auditors of the Company have carried out a limited review of this Statement of unaudited financial results for the quarter ended 30 June 2025.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited



Praveen Akkinepally
Praveen Rao Akkinepally
Managing Director

Place: Bengaluru
Date: 14 August 2025



Initialed For
Identification
Purpose Only

Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli Outer Ring Road,
Bengaluru- 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2025, which are included in the accompanying "Statement of unaudited financial results for the quarter ended June 30, 2025", and the notes thereon (together referred to as the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/ E-300009



Sharmila Ramaswamy
Partner
Membership Number: 215131
UDIN: 25215131BMNPZP2998

Place: Bengaluru
Date: August 14, 2025

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bengaluru - 560 008
T: +91 (80) 40794188

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)

AstraZeneca Pharma India Limited Sustains Growth Momentum in Q1 FY25-26, Advancing Performance Across Diverse Therapies

Revenue rises **36%** in Q1 2025-26; four new approvals reinforce leadership in Oncology

Bengaluru, August 14, 2025: AstraZeneca Pharma India Limited (the Company), a science-led biopharmaceutical company, today announced its financial results for the quarter ended June 30, 2025. Demonstrating consistent growth across therapy areas, the Company reported a revenue increase of **36%** compared to the same period last year, supported by strategic execution, regulatory milestones, and continued portfolio expansion.

Financial performance Summary:

Summary		Q1 2025 Apr -Jun'25 (Value in INR Mn)	Q1 2024 Apr -Jun'24 (Value in INR Mn)
Total Revenue from Operation		5263.1	3,875.2
Profit before exceptional item and tax		750.6	424.0
Profit after exceptional item and tax		558.3	(117.9)
TA-wise performance	Oncology	3702.7	2,394.2
	Biopharmaceuticals (CVRM, R&I and V&I)	1183.2	1,263.3
	Rare Disease	4.2	2.1

Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, “Our strong Q1 performance reflects the power of science-led innovation combined with disciplined execution. Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most.”

Praveen Rao Akkinpally, Country President & Managing Director, said, “Delivering consistent growth across therapy areas reaffirms the strength of our Growth Through Innovation strategy and the passion of our teams to help more patients. At AstraZeneca, we are guided by a bold ambition to transform patient outcomes by delivering the right treatment at the right time. These results are a testament to what is possible when science, and purpose come together.”

Key milestones:

- Received Central Drugs Standard Control Organisation (CDSCO) approval to import for sale and for distribution of Osimertinib tablets for an additional indication in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
- Received CDSCO approval to import for sale and for distribution of trastuzumab deruxtecan for additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients, who have received at least one endocrine therapy in metastatic setting.
- Gained CDSCO approval for additional indication of Osimertinib as a monotherapy, for import for sale and for distribution for the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum based chemoradiation therapy.
- Through the CDSCO approval received for import for sale and for distribution of Benralizumab, it was for additional indication as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Recognitions:

- OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials.
- 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data in clinical trials.
- Featured by Fortune India as a leading multinational transforming healthcare in India.

About AstraZeneca Pharma India Ltd

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Completing its 45 years in India, AstraZeneca Pharma India Limited is headquartered at Bengaluru, Karnataka in India and has a workforce of over 600 employees across the country committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information, please visit our website: <https://www.astrazeneca.in/> or follow us on LinkedIn: [AstraZeneca India](#).